PACAP exerts multiple activities as a hormone and neurotransmitter, and has been proposed to play vital roles in a variety of neuronal functions. PACAP is also involved in insulin secretion from pancreatic β-cells. Recently, we and other groups demonstrated that PACAP-deficient mice (PACAP(−/−)) are viable, but suffer from increased postnatal mortality. To ascertain whether this high mortality is rescued by overexpression of PACAP in peripheral tissue (such as pancreas), we performed a genetic cross between PACAP(−/−) and our recently developed transgenic mice overexpressing PACAP in pancreatic β-cells; and then examined the survival rate of their F 2 progeny. PACAP(−/−) mice were segregated into two groups based on mortality as well as body weight gain: PACAP(−/−) that survived >20 days of age with normal weight gain and PACAP(−/−) that died before 20 days with a marked weight loss. Kaplan–Meier survival analysis demonstrated that PACAP(−/−) mice and those carrying the PACAP transgene have similarly lower survival probability compared with their heterozygous littermates that served as positive controls. Further study using additional tissue-specific transgenic or knockout mouse models will be required to determine the causative defects underlying the high mortality of PACAP(−/−) mice.